Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00354497|
Recruitment Status : Unknown
Verified August 2008 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : July 20, 2006
Last Update Posted : September 20, 2013
RATIONALE: Screening may help doctors find prostate cancer sooner, when it may be easier to treat. The amount of heterocyclic amines in the diet may affect prostate cancer screening results and the risk of prostate cancer.
PURPOSE: This phase II trial is studying prostate cancer screening and dietary heterocyclic amines in African American men.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Other: physiologic testing Other: study of socioeconomic and demographic variables Procedure: evaluation of cancer risk factors Procedure: mutation carrier screening Procedure: study of high risk factors||Phase 2|
- Estimate dietary heterocyclic amine (HA) exposure in African American men who use HA-forming meats and cooking methods.
- Correlate dietary HA exposure with prostate-specific antigen and digital rectal exam screening results (i.e., higher HA exposure with increased abnormality in prostate cancer screening results) in these participants.
OUTLINE: This is a prospective study.
Participants complete a routine medical questionnaire and undergo a detailed dietary interview that focuses on meat consumption, cooking preferences, and other factors that may be associated with prostate cancer risk. Participants then undergo a digital rectal exam (DRE) and blood collection for prostate-specific antigen (PSA) testing (total PSA and % free PSA). Results of PSA testing and DRE, including follow-up instructions (if needed), are sent to the participant 3-4 weeks later.
Blood samples are also examined by phenotypic assays for UV-damage induced nucleotide excision-repair capacity.
PROJECTED ACCRUAL: A total of 800 participants will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||800 participants|
|Official Title:||Prostate Cancer Screening and Dietary HA Exposure in African-Americans: Phase II|
|Study Start Date :||March 2002|
- Dietary heterocyclic amine (HA) exposure in African American men
- Correlation of HA exposure with prostate cancer screening results
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00354497
|United States, California|
|Lawrence Livermore National Laboratory at University of California||Recruiting|
|Livermore, California, United States, 94550|
|Contact: Kenneth T. Bogen, DrPH, MPH, MA, ScD 925-422-0902 email@example.com|
|Alta Bates Summit Medical Center - Summit Campus||Recruiting|
|Oakland, California, United States, 94609|
|Contact: Leslie J. Paine 510-869-8833 firstname.lastname@example.org|
|Principal Investigator:||Kenneth T. Bogen, DrPH, MPH, MA, ScD||Lawrence Livermore National Laboratory at University of California|